(Q33346849)

26 July 2017

title

Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors (English)

1 reference

26 July 2017

1 reference

1 reference

Scott B Cantor

2

0 references

author name string

Linda S Elting

1

1 reference

26 July 2017

Charles G Martin

3

1 reference

26 July 2017

Lois Hamblin

4

1 reference

26 July 2017

Danna Kurtin

5

1 reference

26 July 2017

Edgardo Rivera

6

1 reference

26 July 2017

Saroj Vadhan-Raj

7

1 reference

26 July 2017

Robert S Benjamin

8

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

26 July 2017

1 reference

26 July 2017

volume

97

1 reference

26 July 2017

issue

6

1 reference

26 July 2017

page(s)

1541-1550

1 reference

Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

Risks, costs, and alternatives to platelet transfusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

The quantitative relation between platelet count and hemorrhage in patients with acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Incidence of hemorrhagic complications in patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Conservative Management of Chemotherapeutic-Induced Thrombocytopenia in Women with Gynecologic Cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Controversies in transfusion medicine. Prophylactic platelet transfusion therapy: pro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Prophylactic platelet transfusion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Consensus Conference on Platelet Transfusion, Royal College of Physicians of Edinburgh, 27-28 November 1997. Synopsis of background papers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Current issues with platelet transfusion in patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Optimal dosing and triggers for prophylactic use of platelet transfusions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.11195

1 reference

7 January 2021

Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Blood transfusion costs by diagnosis-related groups in 60 university hospitals in 1995

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Platelet transfusions: utilization and associated costs in a tertiary care hospital

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Platelet Utilization in a University Hospital

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

A survey of blood component use in a German university hospital.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

The bleeding risk index

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Platelet growth factors: potential impact on transfusion medicine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11195

7 January 2021

Identifiers

DOI

10.1002/CNCR.11195

1 reference

26 July 2017

1 reference